Turn Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio
Turn Therapeutics Inc. Common Stock cash flow-to-debt ratio. Turn Therapeutics Inc. Common Stock (TTRX) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2026, meaning its operating cash flow of $-923.36K could theoretically repay 0% of its total liabilities ($16.27 Million) in one year. Check Turn Therapeutics Inc. Common Stock cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Turn Therapeutics Inc. Common Stock (2023–2025)
Cash flow-to-debt ratio of Turn Therapeutics Inc. Common Stock from 2023 to 2025. Historical debt coverage capacity for Turn Therapeutics Inc. Common Stock across 3 annual periods. Also explore Turn Therapeutics Inc. Common Stock (TTRX) equity growth momentum to track the company's year-over-year net asset growth rate.
Turn Therapeutics Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2023–2025)
Turn Therapeutics Inc. Common Stock cash flow-to-debt ratio by year from 2023 to 2025. Year-by-year debt coverage analysis for Turn Therapeutics Inc. Common Stock. For the full cash flow conversion analysis, see TTRX cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | $-2.56 Million | $7.48 Million | ▲ +43.9% |
| 2024 | -0.61x | $-1.36 Million | $2.23 Million | ▲ +14.4% |
| 2023 | -0.71x | $-1.38 Million | $1.93 Million | — |